Obesity increases the risk of Type 2 diabetes, but recent approvals of Ozempic and Wegovy offer new hope. These medications work by mimicking GLP-1 to control insulin and appetite. Despite their benefits, challenges like side effects and insurance coverage exist.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
